BRACAnalysis CDx is an FDA-approved companion diagnostic test for BRCA1 and BRCA2 intended to be used as an aid in treatment decision making for LynparzaTM (olaparib), a PARP inhibitor.1
Personalizing Treatment Decisions in Ovarian Cancer
BRACAnalysis CDx is the first and only FDA-approved laboratory developed test (LDT) that indicates whether or not a patient with ovarian cancer may be eligible for treatment with the PARP inhibitor, Lynparza (olaparib).
Mutations in BRCA1 and BRCA2 are known to cause Hereditary Breast and Ovarian Cancer (HBOC) Syndrome. For more than 20 years, Myriad has been dedicated to understanding mutations in the BRCA genes and providing patients with information about their own genetic profile. Increasing knowledge in the last several years about these genes has impacted individual patient’s medical management options and now mutations in BRCA1 and BRCA2 genes are one of the indications for treatment for patients with ovarian cancer.
Learn more about Myriad’s BRACAnalysis CDx